Targeted dose CT lung cancer screening does not have substantial effect on life-years saved among high risk groups.
Targeting low-dose computed tomography (LDCT) for lung cancer screening for people at highest risk for lung cancer mortality does not offer substantial gains in terms of life-years saved, quality-adjusted life-years (QALYs), or cost-effectiveness, according to a study published in Annals of Internal Medicine.
Researchers from the United States and the Netherlands sought to quantify the value of risk-targeted selection for lung cancer screening compared with National Lung Screening Trial eligibility criteria. The researchers analyzed incremental seven-year mortality, life expectancy, quality-adjusted life-years (QALYs), costs, and cost-effectiveness of screening with LDCT versus chest radiography at each decile of lung cancer mortality risk.
The results showed participants at greater risk for lung cancer mortality were older and had more comorbid conditions and higher screening-related costs. Lung cancer was found in more high-risk patients and targeted screening averted lung cancer deaths over the seven years of the trial, but those at higher risk were also older, had greater smoking exposure, and were more likely to have a preexisting diagnosis of chronic obstructive pulmonary disease. The incremental lung cancer mortality benefits during the first seven years ranged from 1.2 to 9.5 lung cancer deaths prevented per 10,000 person-years for the lowest to highest risk deciles, respectively.
The gradient of benefits across risk groups was attenuated in terms of life-years (extreme decile ratio, 3.6) and QALYs (extreme decile ratio, 2.4). The incremental cost-effectiveness ratios were similar across risk deciles ($75,000 per QALY in the lowest risk decile to $53,000 per QALY in the highest risk decile).
The researchers concluded that although risk targeting may improve screening efficiency in terms of early lung cancer mortality per person screened, the gains in efficiency are attenuated and modest in terms of life-years, QALYs, and cost-effectiveness.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Is Surveillance Imaging Necessary After Primary Radiation for Head and Neck Cancer?
November 13th 2023For patients who had a complete metabolic response to radiation treatment for head and neck cancer, the authors of a recent study found that surveillance imaging with PET/CT, MRI or CT did not improve outcomes in comparison to expectant management.
CT News: American Cancer Society Issues Updated Lung Cancer Screening Recommendations
November 2nd 2023In a newly updated guidance, the American Cancer Society recommends the expansion of annual lung cancer screening with low-dose computed tomography (LDCT) for current or previous smokers 50 to 80 years of age who have a 20-pack-year or greater history of smoking.
Annalise ai Introduces Radiology Triage Platform for Head CT and Chest X-Ray Exams
November 1st 2023Featuring 12 prior FDA clearances for chest X-ray and non-contrast head CT, the Annalise Triage platform may help streamline radiology workflows and prioritize timely diagnosis of urgent conditions.